Lundbeck to present preclinical bexicaserin dual-mode data at European Epilepsy Congress
Lundbeck said preclinical data on bexicaserin’s dual mode of action will be featured in an oral presentation at the European Epilepsy Congress in Athens, Greece, 5–9 September.
VALBY, Denmark, Sept.
3, 2026 // -- Lundbeck today announced that preclinical data on the dual mode of action of bexicaserin will be featured in an oral presentation at the European Epilepsy Congress in Athens, Greece, 5—9 September, alongside additional presentations of clinical and prec…